（原标题：专访中国英国商会主席：英企对华信心日趋乐观，三成计划扩大投资） 南方财经21世纪经济报道记者郑青亭 北京报道 "目前，约三分之一的受访企业计划扩大投资，略超40%的企业保持现状，仅有极少数考虑缩减。市场 规模与完善的基础设施是重要支撑。更重要的是，在全球充满不确定性的环境下，中国展现出更强的可 预测性与稳定性，这对英国企业极具吸引力。" 中国英国商会主席陶克瑞(Chris Torrens)在北京接受21世 纪经济报道记者专访时说道。 12月9日，中国英国商会正式发布《在华英国企业：2025-26年度商业信心调查报告》（以下简称报 告）。报告表明，英国企业总体对其在中国市场的前景日趋乐观，多个重点行业认为明年有望成为疫情 以来业务表现最为强劲的一年。 陶克瑞表示，"这种积极态势与英国对华坚持务实合作的政策密不可分。今年以来，两国重启经济财金 对话，经贸联委会等重要政府间合作机制，为解决市场准入等议题提供了更加稳定、透明的沟通框 架。" 本次调查报告共收录超过300家在中国大陆运营的英国企业的观点与预期。报告显示，英国在华企业全 年营收预期较去年小幅回升，38%的企业预计2025年收入将高于2024年， ...

据港交所文件：华芢生物科技（青岛）股份有限公司 - B通过港交所上市聆讯。 本文源自：金融界AI电报 ...

天眼查App显示，近日，平泉晨鑫生物科技有限公司成立，法定代表人为李志梅，注册资本1万人民 币，经营范围为一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广;互联网 销售（除销售需要许可的商品）;食品销售（仅销售预包装食品）;保健食品（预包装）销售;婴幼儿配方 乳粉及其他婴幼儿配方食品销售;特殊医学用途配方食品销售;母婴生活护理（不含医疗服务）;卫生用品 和一次性使用医疗用品销售;健康咨询服务（不含诊疗服务）;养生保健服务（非医疗）;中医养生保健服 务（非医疗）;个人卫生用品销售;化妆品零售;美发饰品销售;美甲服务;第一类医疗器械销售;第二类医疗 器械销售;医护人员防护用品零售;个人互联网直播服务;针纺织品及原料销售;护理机构服务（不含医疗 服务）;日用化学产品销售;组织文化艺术交流活动;信息咨询服务（不含许可类信息咨询服务）;会议及 展览服务;日用杂品销售;服装服饰零售;纸制品销售;皮革制品销售;工艺美术品及礼仪用品销售（象牙及 其制品除外）;劳动保护用品销售;广告发布（除依法须经批准的项目外，凭营业执照依法自主开展经营 活动）许可项目：婴幼儿洗浴服务;生活美容服务（依法须经批准的项目，经 ...

Core Insights - The article discusses the implementation of the "AI + Enterprise Code Service" initiative in Chongqing, aimed at enhancing digital services for enterprises and grassroots organizations [1] Group 1: Event Overview - A promotional training session for the "AI + Enterprise Code Service" initiative was held in Fuling, focusing on its application in enterprises and grassroots [1] - The training included specialized sessions for key enterprise leaders and service personnel, providing policy interpretations, platform operational training, and experience sharing [3] Group 2: Training Details - Approximately 300 enterprise leaders attended the morning session, where detailed operational training on the platform was provided, including how to submit requests and access services [3] - The session also featured in-depth discussions on financing policies aimed at addressing the challenges of "difficult and expensive financing" for enterprises [3] Group 3: Case Studies and Success Stories - A service specialist shared a case study of Yikela Biotechnology (Chongqing) Co., which improved production efficiency by 23.38%, reduced operational costs by 17.65%, and decreased defective product rates by 28.57% through digital transformation [4] - Another case involved the timely response to a land adjustment request for Chongqing Kalai Composite Materials Co., demonstrating effective inter-departmental coordination [4] Group 4: Service Metrics and Future Plans - Currently, 406 key enterprises are managed within the system, with a 100% satisfaction rate for request handling and a platform login activity rate of 93.6% [5] - The initiative aims to further optimize services and expand the coverage of the "AI + Enterprise Code Service" through additional training sessions in various regions [5]

Core Viewpoint - The China Association for Science and Technology (CAST) Life Sciences Society Consortium is conducting the 2025 "Top Ten Advances in Chinese Life Sciences" selection, emphasizing principles of fairness, justice, and openness [1] Group 1: Selection Process - The selection process involves recommendations from member societies and evaluations by 88 senior experts in fields such as basic life sciences, biotechnology, and clinical medicine [1] - A review committee composed of the consortium's presidium conducts a meeting review to finalize the selected projects [1] Group 2: Selected Projects - The selected projects for 2025 exhibit strong innovation and broad coverage, including: - Discovery of molecules and mechanisms promoting health and longevity through calorie restriction [2] - New approaches for treating central nervous system diseases by promoting the regeneration of new neurons [2] - Innovative breeding strategies for plant resilience driven by epigenetic variations [2] - Breakthroughs in chromosome-level precision editing in plants and animals driven by AI [2] - Exploration of genetic mechanisms in deep-sea animal evolution and adaptation to extreme environments [2] - All selected research projects focus on cutting-edge life sciences and address significant health issues [2] Group 3: Historical Context and Impact - The annual selection of "Top Ten Advances in Chinese Life Sciences" has been conducted since 2015, aimed at promoting research and technological innovation in life sciences [3] - The initiative has been ongoing for 11 years, showcasing major scientific achievements in the field [3] - Following the announcement of results, experts from selected projects are invited to write and publish popular science books and hold outreach events to educate the public about new discoveries in life sciences [3]

Core Perspective - The article discusses the transformation of Tianjin's role in the Beijing-Tianjin-Hebei (Jing-Jin-Ji) coordinated development strategy, shifting from a "defensive" role of merely absorbing functions from Beijing to a "proactive" role of mutual empowerment and deep integration with Beijing [1][2]. Group 1: Strategic Shift - Tianjin's new approach combines "deep integration" and "active introduction" to enhance its regional value and attract resources, aiming to create a positive cycle of development [2][6]. - The focus has shifted from merely relieving Beijing's non-capital functions to establishing a collaborative model where Beijing's innovation capabilities complement Tianjin's manufacturing and cost advantages [2][3]. Group 2: Practical Implementation - The concept of "dual-directional empowerment" is being realized through practical initiatives, such as the successful transformation of research outcomes from Beijing into production in Tianjin [3][4]. - Notable examples include the establishment of AI application centers and agricultural technology implementations in Tianjin, showcasing the effective collaboration between the two cities [2][3]. Group 3: Transportation Integration - Transportation improvements are a key aspect of the integration, with new rail and air connections significantly reducing travel time between Beijing and Tianjin, facilitating closer economic ties [5][6]. - The development of a comprehensive transportation network is expected to enhance the efficiency of cross-province travel, contributing to the overall connectivity of the Jing-Jin-Ji region [5]. Group 4: Collaborative Innovation - Tianjin is actively engaging in high-level collaborations with national research institutions and universities to build advanced research platforms, enhancing its innovation capacity [6]. - The city aims to establish a world-class advanced manufacturing cluster by deepening industrial cooperation with Beijing and Hebei, focusing on key industries such as high-end equipment and cybersecurity [6].

论坛期间，安徽上市公司综合发展能力50强、综合业绩20强、总投资规模20强、营运能力20强、创新能 力20强、ESG绩效20强等系列榜单同步出炉。 在主旨演讲环节，国家金融与发展实验室主任张晓晶发表《"十五五"时期中国资本市场发展展望》的演 讲。深圳证券交易所党委委员、副总经理李辉、北京证券交易所副总经理周箴，分别围绕健全资本市场 功能，赋能创新型中小企业高质量发展等发表演讲。 中国建设银行安徽省分行党委书记、行长关雁翎，广慧并购研究院院长、广慧并购投资联盟主席俞铁 成，智象未来创始人兼首席执行官梅涛，安孚科技董事长夏茂青，从进一步发挥资本市场融资功能，金 融服务实体经济、推动科技创新、加快并购等方面，展开了精彩对话。 此外，论坛还达成并推进系列合作。国元证券与安徽寿县八公山国有林场举行了"安徽省林业碳票+上 市公司ESG场景应用合作签约"；合肥利夫生物科技有限公司、安徽华赛能源科技股份有限公司进行了 企业路演，展示优质项目潜力，搭建资本对接桥梁。 作为本次论坛重头戏，《安徽上市公司发展报告（2025）》（以下简称《报告》）重磅发布。报告围绕 新质生产力、人工智能、县域发展、并购重组、市值管理等资本市场热点话 ...

Group 1 - The establishment of Ningxia Qingdi Biotechnology Co., Ltd. has been registered with a legal representative named Wang Maoxing and a registered capital of 1 million RMB [1] - The company's business scope includes licensed projects such as urban household waste management services, kitchen waste treatment, and road cargo transportation (excluding hazardous goods) [1] - General projects involve research and development of agricultural and forestry waste resource utilization technology, biological feed, special equipment sales, biological organic fertilizer, fertilizer sales, soil pollution control and remediation services, and sales of livestock and fishery feed [1]

今年以来，港股市场迎来生物科技大牛市，绝大部分新上市的生物科技公司上市表现均极为亮眼。 12月9日晚间，港股新股宝济药业进入暗盘阶段，并将于12月10日正式登陆港股市场。作为一家尚未盈 利的生物科技公司，宝济药业如意料之中的那样——获得了众多资本和散户的追捧。 富途牛牛显示，宝济药业的融资申购倍数已超过2691倍： | 融资申购倍数 | | 预计申购倍数 1 | | --- | --- | --- | | 2691.82倍 | | 4533.15倍 | | 募资额(公开) | | 1.00亿 | | 融资申购额 | | 2692.09亿 | | 券商统计 | | | | 券商數:13家 | | | | 富途证券 | | 1650.67亿 | | 辉立证券 | 500.00亿 | | | 老虎国际 | | | | 293.48亿 | | | 宝济药业在暗盘阶段更是大涨112.28%，总市值达到182.55亿港元。 | 56.000+ 最高 | 56.950 今 开 26.380 | | | --- | --- | --- | | 最低 | 26.380 昨 收 26.380 | +29.620 +112.28% ...

Core Viewpoint - The Hong Kong stock market has seen a significant bull market in biotechnology this year, with most newly listed biotech companies performing exceptionally well. Baoyi Pharmaceutical, a pre-profit biotech firm, has garnered substantial interest from capital and retail investors, achieving a subscription multiple of over 2691 times for its IPO [1][2]. Group 1: Company Overview - Baoyi Pharmaceutical was established in 2019 and focuses on four strategic areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals. The total addressable market for these areas in China is projected to reach approximately RMB 50 billion by 2033 [5]. - The company has a pipeline of 12 self-developed products, including three core products (KJ017, KJ103, and SJ02) and several candidates in various clinical stages [5]. Group 2: Financial Performance - For the fiscal years ending December 31, 2023, and 2024, Baoyi Pharmaceutical is expected to report revenues of RMB 0.069 billion and RMB 0.061 billion, respectively, with net losses of RMB 1.60 billion and RMB 3.64 billion [9]. - The company has incurred significant R&D and administrative expenses, leading to continuous net losses. For the six months ending June 30, 2024, a net loss of RMB 1.67 billion is anticipated [9]. Group 3: Market Activity and Stock Performance - During the dark period before its official listing, Baoyi Pharmaceutical's stock surged by 112.28%, reaching a total market capitalization of HKD 18.255 billion [2]. - The stock's trading volume was 1.909 million shares, with a turnover rate of 1.24% [3]. Group 4: Strategic Partnerships - Baoyi Pharmaceutical has entered into a strategic partnership with Anke Biotechnology for the exclusive marketing and sales rights of its core product SJ02 in Greater China, which is expected to accelerate market entry and expand coverage [6]. Group 5: Legal Issues - The company is currently involved in litigation concerning a technology transfer agreement with another biotech firm, which could impact its operations. The lawsuit involves claims for termination of the agreement and compensation totaling RMB 80.2 million [14].